MELBOURNE-BASED listed medical devices and consumables company Paragon Care has announced the acquisition of the immunohaemotology business unit operated by CSL's vaccine offshoot Seqirus for $8.5 million, with the deal expected to settle by Mar 2018.
The immunohaemotology unit is said to be one of Australia's leading manufacturers and distributors of red blood cell reagents and blood grouping reagents, and also distributes automated testing systems used by blood donor centres, hospitals and pathology centres to identify antibodies and antigens in the blood.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Dec 17
